[ad_1]
Photo by Dad Ruvičius (Reuters / Scanpix)
The University of Oxford and the pharmaceutical company AstraZeneca on Tuesday became the first developers of the vaccine against the coronavirus COVID-19 to publish the results of the final phase of clinical trials in a scientific journal.
Added sections “Multiple vaccines will be required” and “Dosage will be decided by supervisory authority.”
This British duo has overcome a major hurdle in the international competition for a safe and effective remedy since the creation of the new pandemic coronavirus.
A study published in the medical journal The Lancet confirms that the vaccine is effective in an average of 70% of cases.
In patients who received two full doses of the vaccine, the effectiveness was 62%, and in the first half of the dose, the effectiveness increased to 90% in the second dose and in the second full dose.
These data are “the first comprehensive efficacy results (studies) published in the peer-reviewed journal” for the COVID-19 vaccine, writes The Lancet.
“It will take several vaccines”
According to Andrew Pollard, director of the Oxford Vaccine Group (OVG) at the University of Oxford, a post in The Lancet shows that vaccine developers are “publishing data in a transparent way.”
According to him, several vaccines will be needed to control the pandemic, because “otherwise we will be in the same situation in six months.”
“It just came to our knowledge then [vakcinų] “It must be a competition with the virus,” he told a news conference.
The dose must be decided by the supervisory authority.
AstraZeneca and the University of Oxford, after publishing a general review of the results last month, withheld questions about their analysis, which used data from 23,000 people in separate trials using different protocols.
They were related to a smaller group whose members initially received half the dose of the vaccine by mistake.
Tuesday’s article confirms that there were no people over 55 in this group of 1,367 people.
According to the authors, they provided additional analysis to the Lancet reviewers, showing that the best results of the group of people vaccinated at half the initial dose did not depend on other factors such as age.
AstraZeneca states that based on these data, the supervisory authority must decide whether to vaccinate people with two full doses, or half the dose first and then the full dose.
“In my opinion, it would be fair to say that more studies are needed to explain these intriguing results,” Pollard said.
It confirmed that half of the starting dose was taken ‘unplanned’, that this was due to a discrepancy in the measurements, but that when the researchers noted an error, these cases were included in the trials with the consent of the supervisory authorities.
The vaccine has already been approved by two other developers, Pfizer and BioNTech, and Moderna says its vaccine is 95% effective.
Britain on Tuesday became the first Western country to launch an immunization program using the Pfizer and BioNTech vaccines. This vaccine was approved for widespread use last week.
The reproduction of information from the BNS news agency in the media and on websites without the written consent of the UAB “BNS” is prohibited.
Write a comment
[ad_2]
